Faron Pharmaceuticals Limited (AIM:FARN) CEO Dr Juho Jalkanen discusses the company's promising developments in cancer treatment, focusing on its lead drug, Bexmarilimab at the Proactive One2One Investor Forum.

Faron is targeting Clever-1, a receptor in macrophages, which plays a crucial role in treatment-resistant tumors. Jalkanen explained that its immunotherapy approach could either turn macrophages against the tumour or prevent them from aiding its growth. The ongoing clinical trials in leukaemia, specifically high-risk myelodysplastic syndrome (MDS), have shown encouraging results, with patients seeing remission and extended survival.

He highlighted that MDS is a highly lethal form of leukaemia, with few treatment options available. Faron's drug has shown the ability to move patients into remission, allowing them to undergo bone marrow transplants, which was previously rare. According to Jalkanen, “We’re making a deadly disease chronic and even enabling cures.” These developments are expected to significantly increase Faron’s market share as the MDS treatment market grows to an estimated $4.1 billion.

Visit Proactive's YouTube channel for more videos, and don't forget to give the video a like, subscribe to the channel, and enable notifications for future content.

#ProactiveInvestors #FaronPharmaceuticals #CancerTreatment #Immunotherapy #LeukemiaResearch #MDS #Biotechnology #CancerInnovation #ClinicalTrials #FDAApproval #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews